204 related articles for article (PubMed ID: 36397155)
1. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy.
Anichini A; Molla A; Nicolini G; Perotti VE; Sgambelluri F; Covre A; Fazio C; Lofiego MF; Di Giacomo AM; Coral S; Manca A; Sini MC; Pisano M; Noviello T; Caruso F; Brich S; Pruneri G; Maurichi A; Santinami M; Ceccarelli M; Palmieri G; Maio M; Mortarini R;
J Exp Clin Cancer Res; 2022 Nov; 41(1):325. PubMed ID: 36397155
[TBL] [Abstract][Full Text] [Related]
2. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract][Full Text] [Related]
3. Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
Di Giacomo AM; Covre A; Finotello F; Rieder D; Danielli R; Sigalotti L; Giannarelli D; Petitprez F; Lacroix L; Valente M; Cutaia O; Fazio C; Amato G; Lazzeri A; Monterisi S; Miracco C; Coral S; Anichini A; Bock C; Nemc A; Oganesian A; Lowder J; Azab M; Fridman WH; Sautès-Fridman C; Trajanoski Z; Maio M
Clin Cancer Res; 2019 Dec; 25(24):7351-7362. PubMed ID: 31530631
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
Lofiego MF; Piazzini F; Caruso FP; Marzani F; Solmonese L; Bello E; Celesti F; Costa MC; Noviello T; Mortarini R; Anichini A; Ceccarelli M; Coral S; Di Giacomo AM; Maio M; Covre A;
J Transl Med; 2024 Mar; 22(1):223. PubMed ID: 38429759
[TBL] [Abstract][Full Text] [Related]
5. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.
Amaro A; Reggiani F; Fenoglio D; Gangemi R; Tosi A; Parodi A; Banelli B; Rigo V; Mastracci L; Grillo F; Cereghetti A; Tastanova A; Ghosh A; Sallustio F; Emionite L; Daga A; Altosole T; Filaci G; Rosato A; Levesque M; Maio M; Pfeffer U; Croce M;
J Exp Clin Cancer Res; 2023 Mar; 42(1):67. PubMed ID: 36934257
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
Khunger A; Piazza E; Warren S; Smith TH; Ren X; White A; Elliott N; Cesano A; Beechem JM; Kirkwood JM; Tarhini AA
PLoS One; 2021; 16(1):e0245287. PubMed ID: 33428680
[TBL] [Abstract][Full Text] [Related]
7. Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Anticancer Agents Med Chem; 2017; 17(2):190-205. PubMed ID: 27109020
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy.
Lofiego MF; Cannito S; Fazio C; Piazzini F; Cutaia O; Solmonese L; Marzani F; Chiarucci C; Di Giacomo AM; Calabrò L; Coral S; Maio M; Covre A; On Behalf Of The EPigenetic Immune-Oncology Consortium Airc Epica Investigators
Epigenomes; 2021 Dec; 5(4):. PubMed ID: 34968251
[TBL] [Abstract][Full Text] [Related]
9. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.
Tiffen J; Wilson S; Gallagher SJ; Hersey P; Filipp FV
Neoplasia; 2016 Feb; 18(2):121-32. PubMed ID: 26936398
[TBL] [Abstract][Full Text] [Related]
10. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy.
Fazio C; Covre A; Cutaia O; Lofiego MF; Tunici P; Chiarucci C; Cannito S; Giacobini G; Lowder JN; Ferraldeschi R; Taverna P; Di Giacomo AM; Coral S; Maio M
Front Pharmacol; 2018; 9():1443. PubMed ID: 30581389
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
14. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
15. A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab.
Kobeissi I; Eljilany I; Achkar T; LaFramboise WA; Santana-Santos L; Tarhini AA
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175874
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
17. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
18. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
Lin J; Lin Y; Huang Z; Li X
Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
[TBL] [Abstract][Full Text] [Related]
19. Genomic and transcriptional changes in IFNγ pathway genes are putative biomarkers of response to ipilimumab immunotherapy in melanoma patients.
Hargadon KM; Győrffy B; McGee TJ
Expert Rev Clin Immunol; 2020 Dec; 16(12):1099-1103. PubMed ID: 33151785
[No Abstract] [Full Text] [Related]
20. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB; Bounova G; Kerzeli I; Anzar I; Simnica D; Aamdal E; Guren T; Clancy T; Mezheyeuski A; Inderberg EM; Mangsbo SM; Binder M; Hovig E; Gaudernack G
J Transl Med; 2022 Sep; 20(1):419. PubMed ID: 36089578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
